Compare
Macrogenics Inc vs Karyopharm Therapeutics Inc. vs Heron Therapeutics, Inc. vs Liquidia Corp
| Latest fiscal year | Macrogenics Inc MGNX | Karyopharm Therapeutics Inc. KPTI | Heron Therapeutics, Inc. HRTX | Liquidia Corp LQDA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $149.50M | $146.07M | $154.90M | $158.32M |
| Revenue growth (YoY) | -0.3% | +0.6% | +7.4% | n/m |
| Gross margin | n/a | n/a | 73.3% | n/a |
| Operating margin | -48.7% | -62.1% | -1.6% | -32.5% |
| Net margin | -49.9% | -134.2% | -13.0% | -43.5% |
| Net income | -$74.62M | -$196.04M | -$20.20M | -$68.92M |
| EPS (Diluted) | -$1.18 | -$17.93 | -$0.12 | -$0.80 |
| Operating cash flow | -$81.04M | -$75.37M | -$27.59M | -$35.69M |
| Free cash flow | -$82.95M | -$75.37M | -$27.91M | -$40.02M |
| Cash & equivalents | $57.22M | $60.54M | $28.65M | $190.68M |
| Total assets | $256.85M | $108.42M | $255.88M | $327.93M |
| Total liabilities | $201.25M | $401.34M | $241.54M | $283.19M |
| Shareholders' equity | $55.59M | -$292.93M | $14.33M | $44.75M |
| Return on year-end equity | -134.2% | n/a | -140.9% | -154.0% |
| Shares outstanding | 63.32M | 18.31M | 188.31M | 87.20M |
Revenue, most recent five fiscal years
| Fiscal year | Macrogenics Inc | Karyopharm Therapeutics Inc. | Heron Therapeutics, Inc. | Liquidia Corp |
|---|---|---|---|---|
| Latest | $149.50M Ended 2025-12-31 | $146.07M Ended 2025-12-31 | $154.90M Ended 2025-12-31 | $158.32M Ended 2025-12-31 |
| 1 year earlier | $149.96M Ended 2024-12-31 | $145.24M Ended 2024-12-31 | $144.28M Ended 2024-12-31 | $14.00M Ended 2024-12-31 |
| 2 years earlier | $58.75M Ended 2023-12-31 | $146.03M Ended 2023-12-31 | $127.04M Ended 2023-12-31 | $17.49M Ended 2023-12-31 |
| 3 years earlier | $151.94M Ended 2022-12-31 | $157.07M Ended 2022-12-31 | $107.67M Ended 2022-12-31 | $15.94M Ended 2022-12-31 |
| 4 years earlier | $77.45M Ended 2021-12-31 | $209.82M Ended 2021-12-31 | $86.35M Ended 2021-12-31 | $12.85M Ended 2021-12-31 |